KCM
PRQR icon

Kynam Capital Management’s ProQR Therapeutics PRQR Stock Holding History

Kynam Capital Management’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.54M Hold
1,566,317
– – 0.16% 37
2025
Q4 		$3.16M Sell
1,566,317
-83,145
-5% -$194K 0.2% 35
2025
Q3 		$3.51M Hold
1,649,462
– – 0.26% 34
2025
Q2 		$3.36M Sell
1,649,462
-100,538
-6% -$164K 0.36% 27
2025
Q1 		$2.33M Hold
1,750,000
– – 0.2% 30
2024
Q4 		$4.64M Buy
+1,750,000
New +$5.56M 0.27% 26

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Kynam Capital Management's PRQR Position: Q1 2026 in Review

Kynam Capital Management held its ProQR Therapeutics (PRQR) position steady in Q1 2026 at 1,566,317 shares worth $2.54M. The position accounts for 0.16% of the portfolio, ranked #37.

Kynam Capital Management first reported a position in PRQR in Q4 2024 and has held it in 6 quarters since. The position peaked at $4.64M in Q4 2024. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

  • Kynam Capital Management held 1,566,317 shares of ProQR Therapeutics worth $2.54M as of Q1 2026.
  • Kynam Capital Management left its ProQR Therapeutics share count unchanged in Q1 2026.
  • ProQR Therapeutics made up 0.16% of Kynam Capital Management's portfolio in Q1 2026, its #37 holding.
  • Kynam Capital Management first reported a position in ProQR Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Kynam Capital Management's ProQR Therapeutics position peaked at $4.64M in Q4 2024.
  • 69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on Kynam Capital Management's 13F filing for Q1 2026, filed 15 May 2026.